<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643693</url>
  </required_header>
  <id_info>
    <org_study_id>P3L-PK-02-US</org_study_id>
    <nct_id>NCT02643693</nct_id>
  </id_info>
  <brief_title>User Acceptability of a Nicotine Lactate Delivery System (P3L)</brief_title>
  <official_title>User Acceptability of a Nicotine Lactate Delivery System Relative to the VUSE e-Cigarette System and Combustible Cigarette Comparators</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philip Morris Products S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide an initial assessment of the acceptability of the Nicotine Lactate
      Delivery System (P3L) after ad libitum use and the ability of combustible cigarette (CC)
      smokers to use P3L to maintain their customary nicotine intake, in a manner comparable with
      their own brand of CC or the VUSE e-cigarette system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration of the study for an individual subject will be between 3 and 8 weeks,
      including 1 day for the screening visit, 3 days for the ad libitum use sessions (P3L, VUSE
      e-cigarette system and subjects' own commercially available non-menthol CC), 1 day for the
      preference evaluation session (subjects will be given the choice of using ad libitum the P3L
      or the VUSE), the 2 to 10 days of interval between each visit, and 7 days for the passive
      safety follow-up period.

      The pharmacokinetics (PK) and pharmacodynamics (PD, i.e., subjective effects) profiles, will
      be evaluated as well as the safety and tolerability of the P3L.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Plasma Concentration of Nicotine/Cotinine After Each ad Libitum Use Session.</measure>
    <time_frame>Measured at 15 minutes and 5 minutes prior to each 3 hour product use to provide baseline measures, then at 15 minutes and 30 minutes after product use period to show change from baseline.</time_frame>
    <description>For each ad libitum use session (P3L, VUSE, and CC), change from baseline plasma concentration of Nicotine/Cotinine was measured from two blood samples collected before product use (to provide baseline measures) and from two blood samples collected following product use (to show change from baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Score of the Short Version of the Questionnaire of Smoking Urges (QSU-brief). Total Score; Factor 1 (Reward); Factor 2 (Relief)</measure>
    <time_frame>QSU-brief questionnaire completed before product use session, then at 60 mins, 120 mins, and 180 mins after starting each product use session.</time_frame>
    <description>The QSU-Brief questionnaire is an instrument used to measure urge to smoke. Subjects were asked to respond to 10 questions, scored from 1 to 7 on a 7-point scale. A score of 1 on this scale indicates a very low urge to smoke, while a score of 7 indicates a very high urge to smoke. Subjects were asked to complete the questionnaire before, during, and after each ad libitum product use session. (P3L, VUSE, and Subjects' Own Brand of Non-menthol CC).
Two factor scores and a total score were derived. Factor 1 represents the desire and intention to smoke with smoking perceived as rewarding, while Factor 2 represents an anticipation of relief from negative effect with an urgent desire to smoke.
Products were compared over all timepoints using a repeated measure model using values after t0.
The model adjusted for baseline value, sequence, and period with repeated measure over time and a random effect in subjects. Adjusted mean over all timepoints, for each timepoint, were estimated.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>P3L Product use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VUSE Product Use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC Product Use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>P3L</intervention_name>
    <description>Ad libitum use for a maximum of three hours.
P3L delivers, on average, 80 µg of nicotine per puff under Health Canada Intense smoking regime.</description>
    <arm_group_label>P3L Product use</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>VUSE</intervention_name>
    <description>Ad libitum use for a maximum of three hours.
VUSE delivers, on average, 80 µg of nicotine per puff based on the CORESTA e-cigarette recommended smoking regime.</description>
    <arm_group_label>VUSE Product Use</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CC</intervention_name>
    <description>Ad libitum use of the subject's own brand of non-menthol CC for a maximum of three hours.</description>
    <arm_group_label>CC Product Use</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Smoking, healthy subject as judged by the Investigator

          -  Subject smoked at least 10 commercially available non-menthol CCs per day for the last
             12 months

          -  Subject does not plan to quit smoking in the next 60 days

        Exclusion Criteria:

          -  As per Investigator judgment, the subject cannot participate in the study for any
             reason (e.g., medical, psychiatric, and/or social reason)

          -  Subject has donated or been in receipt of whole blood or blood products within 3
             months prior to the screening visit

          -  Subject has used tobacco products or nicotine containing products other than CCs
             within 30 days prior to the screening visit

          -  Female subject is pregnant or breast feeding

          -  Female subject does not agree to use an acceptable method of effective contraception

          -  Female subject uses estrogen-containing hormonal contraception or hormone replacement
             therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle Haziza, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Philip Morris Products S.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jed E. Rose, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rose Research Center, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rose Research Center, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res. 2001 Feb;3(1):7-16.</citation>
    <PMID>11260806</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <results_first_submitted>March 9, 2018</results_first_submitted>
  <results_first_submitted_qc>March 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 20, 2019</results_first_posted>
  <last_update_submitted>July 19, 2019</last_update_submitted>
  <last_update_submitted_qc>July 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Conventional cigarette</keyword>
  <keyword>Nicotine lactate delivery system</keyword>
  <keyword>e-cigarette</keyword>
  <keyword>VUSE</keyword>
  <keyword>Combustible cigarette</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study initiated (1st subject screened): 16 November 2015 A demonstration of the P3L system and the VUSE e-cigarette system was given to the subjects.</recruitment_details>
      <pre_assignment_details>Enrolled population = 24 subjects All enrolled subjects met all of the inclusion and none of the exclusion criteria for the study.
Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>P3L/Vuse/CC Product Exposure</title>
          <description>Subjects followed a sequence of product exposure comprised of P3L; VUSE; CC.</description>
        </group>
        <group group_id="P2">
          <title>P3L/CC/Vuse Product Exposure</title>
          <description>Subjects followed a sequence of product exposure comprised of P3L; CC; Vuse.</description>
        </group>
        <group group_id="P3">
          <title>Vuse/CC/P3L Product Exposure</title>
          <description>Subjects followed a sequence of product exposure comprised of Vuse; CC; P3L.</description>
        </group>
        <group group_id="P4">
          <title>Vuse/P3L/CC Product Exposure</title>
          <description>Subjects followed a sequence of product exposure comprised of Vuse; P3L; CC.</description>
        </group>
        <group group_id="P5">
          <title>CC/P3L/Vuse Product Exposure</title>
          <description>Subjects followed a sequence of product exposure comprised of CC; P3L; Vuse.</description>
        </group>
        <group group_id="P6">
          <title>CC/Vuse/P3L Product Exposure</title>
          <description>Subjects followed a sequence of product exposure comprised of the three products (CC; Vuse; P3L).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Adherence Issues</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized subjects who gave informed consent and had exposure to at least one of the investigational products as part of the study (including P3L system, the VUSE e-cigarette system or CC).</population>
      <group_list>
        <group group_id="B1">
          <title>P3L/VUSE/CC Product Exposure</title>
          <description>Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=19 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 19 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Plasma Concentration of Nicotine/Cotinine After Each ad Libitum Use Session.</title>
        <description>For each ad libitum use session (P3L, VUSE, and CC), change from baseline plasma concentration of Nicotine/Cotinine was measured from two blood samples collected before product use (to provide baseline measures) and from two blood samples collected following product use (to show change from baseline).</description>
        <time_frame>Measured at 15 minutes and 5 minutes prior to each 3 hour product use to provide baseline measures, then at 15 minutes and 30 minutes after product use period to show change from baseline.</time_frame>
        <population>All the subjects who gave informed consent and completed all three ad libitum use sessions, without major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>P3L Product Exposure</title>
            <description>Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).</description>
          </group>
          <group group_id="O2">
            <title>VUSE Product Exposure</title>
            <description>Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).</description>
          </group>
          <group group_id="O3">
            <title>CC Product Exposure</title>
            <description>Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Plasma Concentration of Nicotine/Cotinine After Each ad Libitum Use Session.</title>
          <description>For each ad libitum use session (P3L, VUSE, and CC), change from baseline plasma concentration of Nicotine/Cotinine was measured from two blood samples collected before product use (to provide baseline measures) and from two blood samples collected following product use (to show change from baseline).</description>
          <population>All the subjects who gave informed consent and completed all three ad libitum use sessions, without major protocol deviations.</population>
          <units>(ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Average) before session: Nicotine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7621" lower_limit="1.1308" upper_limit="2.7459"/>
                    <measurement group_id="O2" value="2.4113" lower_limit="1.8529" upper_limit="3.1378"/>
                    <measurement group_id="O3" value="1.9446" lower_limit="1.5375" upper_limit="2.4594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline after session: Nicotine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5571" lower_limit="3.5802" upper_limit="8.6255"/>
                    <measurement group_id="O2" value="7.3425" lower_limit="4.7138" upper_limit="11.4371"/>
                    <measurement group_id="O3" value="17.1821" lower_limit="13.7633" upper_limit="21.4500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (Average) before session: Cotinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.554" lower_limit="148.073" upper_limit="225.065"/>
                    <measurement group_id="O2" value="187.559" lower_limit="147.914" upper_limit="237.828"/>
                    <measurement group_id="O3" value="199.547" lower_limit="161.636" upper_limit="246.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline after session: Cotinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.222" lower_limit="10.116" upper_limit="22.905"/>
                    <measurement group_id="O2" value="11.163" lower_limit="5.523" upper_limit="22.561"/>
                    <measurement group_id="O3" value="33.888" lower_limit="24.004" upper_limit="47.842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Score of the Short Version of the Questionnaire of Smoking Urges (QSU-brief). Total Score; Factor 1 (Reward); Factor 2 (Relief)</title>
        <description>The QSU-Brief questionnaire is an instrument used to measure urge to smoke. Subjects were asked to respond to 10 questions, scored from 1 to 7 on a 7-point scale. A score of 1 on this scale indicates a very low urge to smoke, while a score of 7 indicates a very high urge to smoke. Subjects were asked to complete the questionnaire before, during, and after each ad libitum product use session. (P3L, VUSE, and Subjects' Own Brand of Non-menthol CC).
Two factor scores and a total score were derived. Factor 1 represents the desire and intention to smoke with smoking perceived as rewarding, while Factor 2 represents an anticipation of relief from negative effect with an urgent desire to smoke.
Products were compared over all timepoints using a repeated measure model using values after t0.
The model adjusted for baseline value, sequence, and period with repeated measure over time and a random effect in subjects. Adjusted mean over all timepoints, for each timepoint, were estimated.</description>
        <time_frame>QSU-brief questionnaire completed before product use session, then at 60 mins, 120 mins, and 180 mins after starting each product use session.</time_frame>
        <population>All the subjects who gave informed consent and completed all three ad libitum use sessions, without major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>P3L Product Exposure</title>
            <description>Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).</description>
          </group>
          <group group_id="O2">
            <title>VUSE Product Exposure</title>
            <description>Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).</description>
          </group>
          <group group_id="O3">
            <title>CC Product Exposure</title>
            <description>Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Score of the Short Version of the Questionnaire of Smoking Urges (QSU-brief). Total Score; Factor 1 (Reward); Factor 2 (Relief)</title>
          <description>The QSU-Brief questionnaire is an instrument used to measure urge to smoke. Subjects were asked to respond to 10 questions, scored from 1 to 7 on a 7-point scale. A score of 1 on this scale indicates a very low urge to smoke, while a score of 7 indicates a very high urge to smoke. Subjects were asked to complete the questionnaire before, during, and after each ad libitum product use session. (P3L, VUSE, and Subjects' Own Brand of Non-menthol CC).
Two factor scores and a total score were derived. Factor 1 represents the desire and intention to smoke with smoking perceived as rewarding, while Factor 2 represents an anticipation of relief from negative effect with an urgent desire to smoke.
Products were compared over all timepoints using a repeated measure model using values after t0.
The model adjusted for baseline value, sequence, and period with repeated measure over time and a random effect in subjects. Adjusted mean over all timepoints, for each timepoint, were estimated.</description>
          <population>All the subjects who gave informed consent and completed all three ad libitum use sessions, without major protocol deviations.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Score - Over all timepoints</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" lower_limit="3.36" upper_limit="4.36"/>
                    <measurement group_id="O2" value="3.08" lower_limit="2.58" upper_limit="3.58"/>
                    <measurement group_id="O3" value="1.93" lower_limit="1.43" upper_limit="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score - t0 + 60mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" lower_limit="3.51" upper_limit="4.52"/>
                    <measurement group_id="O2" value="3.24" lower_limit="2.74" upper_limit="3.74"/>
                    <measurement group_id="O3" value="2.09" lower_limit="1.58" upper_limit="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score - t0 + 120mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.84" lower_limit="3.33" upper_limit="4.36"/>
                    <measurement group_id="O2" value="3.07" lower_limit="2.56" upper_limit="3.58"/>
                    <measurement group_id="O3" value="1.91" lower_limit="1.40" upper_limit="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score - t0 + 180mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.71" lower_limit="3.20" upper_limit="4.23"/>
                    <measurement group_id="O2" value="2.94" lower_limit="2.42" upper_limit="3.45"/>
                    <measurement group_id="O3" value="1.78" lower_limit="1.27" upper_limit="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 1 - Over all timepoints</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.97" lower_limit="4.39" upper_limit="5.54"/>
                    <measurement group_id="O2" value="4.11" lower_limit="3.54" upper_limit="4.68"/>
                    <measurement group_id="O3" value="2.15" lower_limit="1.58" upper_limit="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 1 - t0 + 60mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" lower_limit="4.28" upper_limit="5.46"/>
                    <measurement group_id="O2" value="4.48" lower_limit="3.89" upper_limit="5.06"/>
                    <measurement group_id="O3" value="2.53" lower_limit="1.94" upper_limit="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 1 - t0 + 120mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.99" lower_limit="4.33" upper_limit="5.64"/>
                    <measurement group_id="O2" value="4.11" lower_limit="3.46" upper_limit="4.77"/>
                    <measurement group_id="O3" value="2.08" lower_limit="1.42" upper_limit="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 1 - t0 + 180mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.05" lower_limit="4.43" upper_limit="5.66"/>
                    <measurement group_id="O2" value="3.74" lower_limit="3.13" upper_limit="4.35"/>
                    <measurement group_id="O3" value="1.84" lower_limit="1.23" upper_limit="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 2 - Over all timepoints</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" lower_limit="2.34" upper_limit="3.36"/>
                    <measurement group_id="O2" value="2.15" lower_limit="1.64" upper_limit="2.66"/>
                    <measurement group_id="O3" value="1.60" lower_limit="1.10" upper_limit="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 2 - t0 + 60mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.95" lower_limit="2.43" upper_limit="3.48"/>
                    <measurement group_id="O2" value="2.25" lower_limit="1.73" upper_limit="2.78"/>
                    <measurement group_id="O3" value="1.71" lower_limit="1.19" upper_limit="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 2 - t0 + 120mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" lower_limit="2.33" upper_limit="3.35"/>
                    <measurement group_id="O2" value="2.14" lower_limit="1.63" upper_limit="2.65"/>
                    <measurement group_id="O3" value="1.59" lower_limit="1.09" upper_limit="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 2 - t0 + 180mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" lower_limit="2.24" upper_limit="3.28"/>
                    <measurement group_id="O2" value="2.06" lower_limit="1.54" upper_limit="2.58"/>
                    <measurement group_id="O3" value="1.51" lower_limit="1.00" upper_limit="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over the entire study duration of up to 5 months, with individual subject participation of between three and 11 weeks from the signature of the Informed Consent Form (ICF) until the end of the safety follow-up period.</time_frame>
      <desc>The safety was assessed in the safety population, consisting of all randomized subjects who gave informed consent and had exposure to at least one of the investigational products as part of the study (including P3L system, the VUSE e-cigarette system or CC).
Overall safety population = 22 subjects; P3L exposure = 21 subjects; VUSE exposure = 19 subjects; CC exposure = 19 subjects.</desc>
      <group_list>
        <group group_id="E1">
          <title>P3L Product</title>
          <description>Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).</description>
        </group>
        <group group_id="E2">
          <title>VUSE Product</title>
          <description>Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).</description>
        </group>
        <group group_id="E3">
          <title>CC Product</title>
          <description>Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling Jittery</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Unevaluable Event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Disturbance In Attention</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nasal Discomfort</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.
The Intellectual Property rights and research results from the present study belong to the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christelle Haziza, PhD</name_or_title>
      <organization>Philip Morris Products S.A.</organization>
      <phone>+41 (58) 242 11 11</phone>
      <email>ClinicalTrials.PMI@pmi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

